Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas M Polasek

Showing results (11-20 of 74) with videos related to

Pageof 8
Sort By:
Frontiers in Medicine|June 20, 2025
Povidone-iodine nasal spray (Nasodine<sup>®</sup>) for the common cold: a randomized, controlled, double-blind, Phase III clinical trialThomas M Polasek, Peter L Friedland
Therapeutic Advances in Drug Safety|August 2, 2014
The ABCD of clinical pharmacokineticsMatthew P Doogue, Thomas M Polasek
Clinical Pharmacology and Therapeutics|February 8, 2024
Beyond Population-Level Targets for Drug Concentrations: Precision Dosing Needs Individual-Level Targets that Include Superior Biomarkers of Drug ResponsesThomas M Polasek, Richard W Peck
Clinical Pharmacology and Therapeutics|May 26, 2025
Caution with PBPK Modeling Based on the In Vitro Kinetics for Bilirubin Hepatic Uptake and Glucuronidation: Commentary on Dong et alJohn O Miners, Thomas M Polasek
European Journal of Clinical Pharmacology|January 18, 2006
Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrateThomas M Polasek, John O Miners
British Journal of Clinical Pharmacology|July 31, 2007
Time-dependent inhibition of human drug metabolizing cytochromes P450 by tricyclic antidepressantsThomas M Polasek, John O Miners
British Journal of Clinical Pharmacology|October 1, 2008
Macrolide-theophylline interactions: no role for the inhibition of cytochrome P4501A2Thomas M Polasek, John O Miners
Australian Journal of General Practice|July 1, 2019
Pharmacogenomics in general practice: The time has comeThomas M Polasek, Kym Mina, Graeme Suthers
Trials|July 18, 2024
Personality vulnerabilities and adverse event reporting in phase 1 clinical studiesJoanna Skommer, Krish Gunesh, Thomas M Polasek
International Forum of Allergy & Rhinology|June 13, 2024
Phase 1 study of the iodine absorption, safety, and tolerability of a 0.5% povidone-iodine nasal spray (Nasodine)Peter L Friedland, Thomas M Polasek, Duncan Topliss
Pageof 8

Showing results (11-20 of 74) with videos related to

Sort By:
Pageof 8
Frontiers in Medicine|June 20, 2025
Povidone-iodine nasal spray (Nasodine<sup>®</sup>) for the common cold: a randomized, controlled, double-blind, Phase III clinical trialThomas M Polasek, Peter L Friedland
Therapeutic Advances in Drug Safety|August 2, 2014
The ABCD of clinical pharmacokineticsMatthew P Doogue, Thomas M Polasek
Clinical Pharmacology and Therapeutics|February 8, 2024
Beyond Population-Level Targets for Drug Concentrations: Precision Dosing Needs Individual-Level Targets that Include Superior Biomarkers of Drug ResponsesThomas M Polasek, Richard W Peck
Clinical Pharmacology and Therapeutics|May 26, 2025
Caution with PBPK Modeling Based on the In Vitro Kinetics for Bilirubin Hepatic Uptake and Glucuronidation: Commentary on Dong et alJohn O Miners, Thomas M Polasek
European Journal of Clinical Pharmacology|January 18, 2006
Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrateThomas M Polasek, John O Miners
British Journal of Clinical Pharmacology|July 31, 2007
Time-dependent inhibition of human drug metabolizing cytochromes P450 by tricyclic antidepressantsThomas M Polasek, John O Miners
British Journal of Clinical Pharmacology|October 1, 2008
Macrolide-theophylline interactions: no role for the inhibition of cytochrome P4501A2Thomas M Polasek, John O Miners
Australian Journal of General Practice|July 1, 2019
Pharmacogenomics in general practice: The time has comeThomas M Polasek, Kym Mina, Graeme Suthers
Trials|July 18, 2024
Personality vulnerabilities and adverse event reporting in phase 1 clinical studiesJoanna Skommer, Krish Gunesh, Thomas M Polasek
International Forum of Allergy & Rhinology|June 13, 2024
Phase 1 study of the iodine absorption, safety, and tolerability of a 0.5% povidone-iodine nasal spray (Nasodine)Peter L Friedland, Thomas M Polasek, Duncan Topliss
Pageof 8